Results 231 to 240 of about 147,929 (284)

Tacrolimus Induced Hypertension and Vascular Remodeling Includes Mechanisms of Cellular Senescence—The Protective Effect of Valsartan

Acta Physiologica, Volume 242, Issue 4, April 2026.
ABSTRACT Aim Calcineurin inhibitors (CNI) such as tacrolimus (Tac) are the first‐line treatment to prevent transplant rejection. However, CNI have adverse effects on blood vessels and renal function, which may be linked to cellular senescence. Valsartan, a common angiotensin II type 1 receptor (AT1R) blocker, exhibits anti‐senescence properties.
Lingyan Fei, Xiaohua Wang, Lingyi Kong, Tianjiao Cui, Pratik H. Khedkar, Yunxiu Xiang, Dongliang Zhao, Junxuan Fang, Yulin Liang, Yangyang Zhang, Nan Xu, Xingyu Qiu, Liang Zhao, Gensheng Zhang, Yan Lei, Chun Tang, Kongyang Ma, Liwei Lu, Jin Wei, En Yin Lai, Pontus B. Persson, Andreas Patzak, Zhihua Zheng, Shan Jiang   +23 more
wiley   +1 more source

Long-term bladder and renal outcomes after cutaneous vesicostomy closure in pediatric patients with non-neurogenic bladder. [PDF]

Investig Clin Urol
Kang K, Kim SW, Park JE, Han SW, Lee YS.
europepmc   +1 more source

Leaflets promoting GFR technologies

Leaflets promoting GFR ...
openaire   +1 more source

On the measurement of glomerular filtration rate: An odyssey into the milieu intérieur

Experimental Physiology, EarlyView.
Anders Møller Greve, Anna Agnes Lytzen, Hrefna Sæunn Einarsdóttir, Michael Perch, Ronan M. G. Berg   +4 more
wiley   +1 more source

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection—General and Special Populations

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 7, Page 945-954, April 2026.
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Lung‐Yi Mak, Tsung‐Hui Hu, Desmond Y. H. Yap   +2 more
wiley   +1 more source

Implementing Kidney Disease: Improving Global Outcomes 2024 Through Laboratory-Estimated GFR Across Ages. [PDF]

Kidney Int Rep
De Mul A, Bres E, Bacchetta J, Chardon L, Letourneau P, Lemoine S, Dubourg LD.   +6 more
europepmc   +1 more source

The anti‐fibrotic effects of novel heart failure pharmacotherapies in advanced heart failure patients

British Journal of Pharmacology, Volume 183, Issue 7, Page 1502-1516, April 2026.
Background and Purpose Novel heart failure (HF) pharmacotherapies, including angiotensin receptor‐neprilysin inhibitor (ARNI) and sodium‐glucose cotransporter 2 inhibitors (SGLT2is), may confer cardiovascular benefits by attenuating myocardial fibrosis. However, direct evidence from human failing myocardial samples is limited.
Dávid Nagy, Tamás Radovits, Tímea Bálint, Zoltán Horváth, Petra Kocsis‐Balogh, Ákos Gergely Tóth, Attila Oláh, Alex Ali Sayour, Bálint András Barta, Béla Merkely, Mihály Ruppert   +10 more
wiley   +1 more source

The Physiology of Lived Experience: And then there was one – the story of a radical nephrectomy

Experimental Physiology, EarlyView.
Michael J. Shattock
wiley   +1 more source

Prevalence and outcomes of DKA in type 1 and type 2 DM patients treated and not treated with SGLT‐2 inhibitors

Diabetic Medicine, Volume 43, Issue 4, April 2026.
Abstract Aim To compare the clinical characteristics, biochemical presentation, and short‐ and long‐term outcomes of DKA in hospitalized adults with T1DM and T2DM, including the impact of SGLT2 inhibitor therapy. Methods A retrospective cohort of 2283 adults (838 with T1DM; 1445 with T2DM) hospitalized with DKA between 2013 and 2023 across Clalit ...
Elena Chertok Shacham, Sireen Sharif, Rageh Tatoor, Snait Ayalon   +3 more
wiley   +1 more source

Safety of locally applied antibiotics in orthopaedic trauma surgery: descriptive results from a prospective cohort study. [PDF]

J Bone Jt Infect
Vanvelk N, Van Lieshout EMM, Nugteren LHT, Plaisier AC, Van der Pot R, Bethlehem C, Metsemakers WJ, Obremskey WT, Verhofstad MHJ.   +8 more
europepmc   +1 more source